Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

563
Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the...
563
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

323
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
323
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

81
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
81

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.

American journal of respiratory and critical care medicine·2026
Same author

Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.

Pulmonary therapy·2026
Same author

Sociodemographic Determinants of Hospitalized Exacerbations in Exposure-Defined COPD Phenotypes: A Nationwide Prospective Cohort Study in China.

International journal of chronic obstructive pulmonary disease·2026
Same author

Improving the diagnostic performance of troponin assays for acute myocardial infarction in renal impairment.

Heart (British Cardiac Society)·2026
Same author

Ensuring continued access to essential inhaled respiratory medications: a call to action from the Inhaled Respiratory medicine Innovation and environmental Sustainability (IRIS) group.

The European respiratory journal·2026
Same author

Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid Use.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Jun 28, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K

Development and validation of a new algorithm for improved cardiovascular risk prediction.

Julia Hippisley-Cox1, Carol A C Coupland2,3, Mona Bafadhel4

  • 1Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK. julia.hippisley-cox@phc.ox.ac.uk.

Nature Medicine
|April 18, 2024
PubMed
Summary

A new QR4 algorithm improves cardiovascular disease (CVD) risk prediction by incorporating novel factors like certain cancers and Down syndrome. This tool offers superior 10-year CVD risk estimation for men and women in the UK compared to existing scores.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.7K

Related Experiment Videos

Last Updated: Jun 28, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.1K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.7K

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • Cardiovascular disease (CVD) remains a leading cause of mortality globally.
  • Existing risk prediction algorithms, such as QRISK3, provide valuable tools for clinicians.
  • There is a continuous need to refine CVD risk assessment by incorporating novel risk factors.

Purpose of the Study:

  • To derive and externally validate a new cardiovascular disease (CVD) risk algorithm, named QR4.
  • To incorporate novel risk factors into CVD risk prediction separately for men and women.
  • To compare the performance of QR4 against existing CVD risk scores like QRISK3, SCORE2, and ASCVD.

Main Methods:

  • Utilized health data from 9.98 million UK adults for algorithm derivation and 6.79 million for external validation.
  • Employed cause-specific Cox models to develop predictive models for 10-year CVD risk.
  • Externally validated the QR4 algorithm and compared its performance (C-statistic) against QRISK3, SCORE2, and ASCVD risk scores.

Main Results:

  • Identified seven novel risk factors for both men and women (e.g., brain cancer, lung cancer, Down syndrome, COPD) and two additional for women (pre-eclampsia, postnatal depression).
  • QR4 demonstrated a higher C-statistic than QRISK3 in both women (0.835 vs. 0.831) and men (0.814 vs. 0.812) upon external validation.
  • QR4 exhibited superior accuracy compared to ASCVD and SCORE2 risk scores in both sexes.

Conclusions:

  • The QR4 algorithm offers enhanced cardiovascular disease risk prediction in the UK population.
  • Incorporation of novel risk factors significantly improves the accuracy of CVD risk assessment.
  • QR4 identifies new at-risk groups and provides a more precise tool for clinical decision-making compared to international scoring systems.